ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference
January 02 2020 - 8:30AM
Business Wire
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Mark Enyedy, President and CEO, will present
at the upcoming 38th Annual J.P. Morgan Healthcare Conference in
San Francisco, CA. The presentation is scheduled for 9:30am PT
(12:30pm ET) on January 16, 2019.
Following the presentation, Mr. Enyedy will be joined by other
members of ImmunoGen’s management team for a question-and-answer
session at 10:00am PT (1:00pm ET).
A webcast of the presentation and question-and-answer session
will be accessible live through the “Investors & Media” section
of the Company’s website, www.immunogen.com; a replay will be
available in the same location.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200102005091/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting
Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024